Leading global law firm Herbert Smith Freehills Kramer has advised Morgan Stanley Asia Limited, CITIC Securities (Hong Kong) Limited and CLSA Limited as joint sponsors and underwriters of Nanjing Leads Biolabs Co., Ltd. (09887.HK)'s H share listing on the Main Board of the Hong Kong Stock Exchange.

"This latest listing reflects continued momentum in Hong Kong’s healthcare IPO market,” said Hong Kong partner Matt Emsley. “We’re proud to support transactions that reinforce the city’s role as a gateway for both innovation and international capital."

Leads Biolabs is a clinical-stage biotechnology company working on the discovery, development and commercialisation of new therapies in oncology, autoimmune and other severe diseases.

The company listed on the Hong Kong Stock Exchange on 25 July 2025. This is the third healthcare IPO on which the firm has advised in the past two months.

"We congratulate Leads Biolabs on its successful listing on the Hong Kong Stock Exchange," said Beijing partner Stanley Xie. "Our track record in healthcare IPOs speaks to the depth of our sector expertise and commitment to clients' success."

Herbert Smith Freehills Kramer is a leading adviser to healthcare companies listing in Hong Kong. Over the past five years, the firm has advised on 27 healthcare listings on the HKEX, including Medtide (03880.HK), Jiangsu Hengrui Pharmaceuticals (01276.HK), QuantumPharm Inc. (02228.HK), Lepu ScienTech Medical (02291.HK), Biocytogen Pharmaceuticals (02315.HK), CARsgen Therapeutics (02171.HK), Abbisko (02256.HK), Simcere (02096.HK), among others.

Partners Matt Emsley, Stanley Xie and Jin Kong* led a cross-office team advising the underwriters, assisted by Agatha Shen, Sean Ji, Crystal Chan, Kaiwen Sun, Haiyun Chen, Ting Wang and Primrose Ho.

Legal manager Marine Jin led Herbert Smith Freehills Kewei Joint Operation’s Digital Legal Delivery business to provide high-efficiency solutions for verification and other document-intensive processes during the listing, assisted by Jean Zhou, Chloe Hu, Chunqin Li and Mia Jin.

*According to regulatory requirements, Jin Kong's official title is Senior Registered Foreign Lawyer in Hong Kong.

Key contacts

Stanley Xie photo

Stanley Xie

Chief Representative, Head of Beijing, Mainland China and Beijing

Jin Kong photo

Jin Kong

Senior Registered Foreign Lawyer (New York, USA), Hong Kong


Media contact

For further information on this news article, please contact:

Sally Greig

Head of Communications, Asia

Hong Kong

Vivian Huang

Communications Manager, China

Beijing

Stay in the know

Receive timely insights and briefings from HSF Kramer, tailored to keep you informed and ahead

Subscribe now
Mainland China Hong Kong Equity capital markets Capital markets Corporate Pharmaceuticals and healthcare Matthew Emsley Stanley Xie Jin Kong